

## **RESULTS OF CIS-PLATINUM TREATMENT OF BREAST CANCER PATIENTS WITH BRCA1 MUTATION.**

Steven Narod<sup>1</sup>, Tomasz Byrski<sup>2</sup>, Elżbieta Marczyk<sup>3</sup>, Rafał Wiśniowski<sup>4</sup>, Marek Świec<sup>5</sup>, Tomasz Huzarski<sup>6</sup>, Cezary Cybulski<sup>6</sup>, Tadeusz Dębniak<sup>6</sup>, Jacek Gronwald<sup>6</sup>, Jan Lubiński<sup>6</sup>

1 Women's College Hospital, University of Toronto, Toronto, Canada.

2 Department of Oncology, Pomeranian Medical University, Szczecin, Poland

3 Department of Surgical Oncology, Oncology Center, Kraków, Poland

4 Department of Oncology, Oncology Center, Bielsko-Biała, Poland

5 Department of Oncology, Oncology Center, Opole, Poland

6 International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.

The aim of this study is to evaluate the effectiveness of neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation. One 131 women with breast cancer and a BRCA1 mutation, who were diagnosed with stage I to III breast cancer between December 2006 and June 2017, were treated with cisplatin 75 mg/m<sup>2</sup> every 3 weeks for four cycles, followed by mastectomy and conventional chemotherapy. Information was collected on clinical stage, grade, hormone receptor status, and Her2neu status prior to treatment. pCR was determined by review of surgical specimens. Medium time of observation was 52 months. One hundred 131 patients were enrolled in the study. A pCR was observed in 79 (60 %) patients and pPR in 46 (35%). Between 79 patients who obtained pCR 1 patient died.

Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer.